Form 4: Neogenomics Director Felicia Williams Acquires Stock Options and Restricted Stock Units

Director Felicia Williams reports acquisition of stock options and restricted stock units in Neogenomics Inc.

Summary

• On November 1, 2024, Felicia Williams, a director of Neogenomics Inc., acquired 5,430 stock options with an exercise price of $13.59.
• These options are exercisable starting June 1, 2025, and expire on June 1, 2034.
• Williams also acquired 7,160 restricted stock units that vest starting June 1, 2025.
• Following these transactions, Williams directly owns 5,430 stock options and 7,160 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock options and restricted stock units granted to a director. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation practices.

Positives

• The acquisition of stock options and restricted stock units by a director may indicate confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options and restricted stock units aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates